Palisade Bio Files for 8.9M Share Registration for Selling Stockholders

Palisade Bio has filed to register up to 8.9M shares of common stock for resale by selling stockholders. The shares include 8.64M issuable upon exercise of a warrant from a private placement and 259,134 from placement agent warrants. Palisade Bio will not receive any proceeds from the resale of these shares.

Palisade Bio, Inc. (NASDAQ: PALI), a biopharmaceutical company focused on developing innovative therapies for inflammatory bowel disease (IBD), has filed to register up to 8.9 million shares of common stock for resale by selling stockholders. The shares include 8.64 million issuable upon exercise of a warrant from a private placement, and 259,134 from placement agent warrants. Notably, Palisade Bio will not receive any proceeds from the resale of these shares [2].

This move comes amidst significant financial improvements and key advancements in the development of its lead product candidate, PALI-2108. The company's Form 10-Q report for the second quarter of 2025 highlights a 32% decrease in net loss compared to the same period in 2024, primarily due to reduced research and development expenses. The net loss per share for the three months ended June 30, 2025, also improved from $(3.32) in 2024 to $(0.58) [1].

The registration of these shares for resale is part of Palisade Bio's strategy to manage its capital structure and facilitate the development of PALI-2108, which is currently in Phase 1 clinical trials. The company's focus on advancing PALI-2108 through clinical trials has led to a shift in its research and development expenses, with a significant decrease in preclinical joint development costs [1].

Palisade Bio's management anticipates submitting an Investigational New Drug Application (IND) with the FDA and commencing U.S. clinical trials for PALI-2108 in the first half of 2026. The company's operational focus has shifted towards clinical trials and commercialization activities for PALI-2108, assuming all related costs and responsibilities [1].

References:
[1] https://www.tradingview.com/news/tradingview:ef24e2c1799c4:0-palisade-bio-inc-sec-10-q-report/
[2] https://seekingalpha.com/news/4486237-palisade-bio-registers-89m-shares-for-resale-by-selling-stockholders